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Abstract Calcium (Ca)-containing phosphate binders have
been recommended for the treatment of hyperphosphatemia
in children with chronic kidney disease. To study the effects
of high Ca levels on trabecular bone volume (BV) and
osteoprotegerin (OPG) expression in uremic young rats, a
model of marked overcorrection of secondary hyperpara-
thyroidism was created by providing a diet of high Ca to
5/6 nephrectomized young rats (Nx-Ca) for 4 weeks. The
results of chondrocyte proliferation and apoptosis, osteo-
clastic activity, OPG expression and BV were compared
among intact rats given the control diet, intact rats given a
high Ca diet and 5/6 nephrectomized rats given the control
diet (Nx-Control) and the high Ca diet (Nx-Ca). Ionized Ca
levels were higher and parathyroid hormone levels were
lower in Nx-Ca rats than in the other groups. Final weight,
final length and final tibial length of Nx-Ca rats were
significantly less than those of the other groups, although
the length gain did not differ among the groups. The
hypertrophic zone width was markedly enlarged in Nx-Ca
rats. Chondrocyte proliferation rates did not differ among
the groups, whereas osteoclastic activity was decreased in
Nx-Ca rats compared with the Nx-Control animals. The
OPG expression and BV were increased in Nx-Ca rats
compared with the Nx-Control rats. Increased BV should
improve bone strength, whereas disturbance of osteoclasto-
genesis interferes with bone remodeling. Bone quality has
yet to be determined in high Ca-fed uremic young rats.
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Introduction
Chronic kidney disease mineral and bone disorders
(CKD-MBD) are abnormalities of bone and mineral
metabolism found in patients with CKD. Bone pathology
occurs as an aspect of CKD-MBD and is called renal
osteodystrophy (ROD). ROD is characterized by bone
lesions ranging from high-turnover lesions of secondary
hyperparathyroidism (SHPT) to low-turnover lesions of
osteomalacia and adynamic bone (AD). Overall, SHPT
remains the most common type of ROD afflicting
children with CKD [1]. However, the incidence of AD
has been increasing over the past decade. This increase has
been attributed to aggressive interventions in managing SHPT
patients with parathyroidectomy and active vitamin D and
calcium (Ca) supplementation [2].
Dietary phosphate reduction, active vitamin D supple-
mentation and Ca-containing phosphate binders are
recommended for the treatment of hyperphosphatemia
in patients with CKD to prevent SHPT. Growth impair-
ment along with a reduction of tibial length have been
observed in nephrectomized rats given high Ca. The
hypertrophic zone of the growth plates in these animals
were enlarged and associated with a decrease of matrix
degradation and osteoclastogenesis [3].
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At the molecular level, osteoclastogenesis is regulated by
the receptor–activator of nuclear factor kappa beta
(RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG)
system. OPG is a soluble decoy receptor competing with
RANK, which is found on the surface of osteoclasts, in
bound form to RANKL which is expressed on osteoblasts.
The competitive binding of OPG to RANKL results in the
inhibition of osteoclast proliferation and differentiation [4].
In nephrectomized rats given high Ca, widening growth
plates could potentially be the result of increased OPG
expression by hypertrophic chondrocytes, and these might
prevent osteoclastic breakdown of growth plate calcified
cartilage. However, OPG expression in the growth plates of
nephrectomized rats given high Ca has not yet been
characterized. The aim of this study was to assess OPG
expression in the growth cartilage of uremic rats receiving
high Ca. We also measured trabecular bone volume (BV) in
this animal model as BV is known to be increased in mice
overexpressing the OPG gene [5] and in ovariectomized
animals given recombinant OPG [6].
Material and methods
Forty-seven male weanling Sprague-Dawley rats each
weighing approximately 110 gm (Harlan Laboratories,
San Diego, CA) were obtained at 4 weeks of age and
housed under similar conditions (12/12-h light/dark cycle,
ambient temperature 22±3°C). All study procedures were
reviewed and approved by the Animal Protection Commit-
tee of UCLA (Los Angeles, CA). The rats were supplied
with water and standard rat chow containing 18.6% protein,
0.8% Ca, 0.7% phosphorus (P), 0.2% magnesium (Mg) and
4.2 IU/g vitamin D (Purina Mills, Indianapolis, IN) ad
libitum. After 1 week of acclimatization, 25 rats underwent
a two-stage 5/6 nephrectomy to produce renal failure, as
previously described [7]. Twenty-two rats underwent sham
nephrectomy in two stages corresponding to the time of the
actual two-stage 5/6 nephrectomy. The day after completing
the second set of surgical procedures, all of the animals
were weighed and the body length measured from the tip of
the noses to the end of the tails.
Eleven sham-nephrectomized control (Intact-Control,
n=11) animals and 11 nephrectomized control (Nx-
Control, n=11) animals were fed a standard rat chow as
described above. By contrast, 14 nephrectomized rats were
placed on a high Ca diet containing 2.5% Ca and 0.7% P,
0.2% Mg and 4.2 IU/g vitamin D (Nx-Ca, n=14). Eleven
other sham-nephrectomized rats were also fed a high Ca
diet (Intact-Ca, n=11). Animals from each group were
maintained on the specified diets for 4 weeks. In order to
ensure an equivalent caloric intake between the control
and the nephrectomized animals, the rats were pair-fed by
feeding the control rats the same amount of food that had
been consumed the previous day by their nephrectomized
counterparts.
After 4 weeks, bromodeoxyuridine (BrdU, 100 mg/kg;
Zymed Laboratories, San Francisco, CA) was administered
intraperitoneally approximately 2 h prior to sacrifice. At
sacrifice, blood was obtained by cardiac puncture and
tissues were fixed by trans-cardiac perfusion as previously
described [3]. Blood was centrifuged and serum was stored
at -70°C until further use. Tibiae were excised, and the final
tibial length was reported as the average of the triplicate
measurements between the proximal and distal articular
surfaces using an electronic caliper. Bones were then
immersed in 4% paraformaldehyde/phosphate buffered
saline (PFA/PBS) for 48 h, and the tibiae decalcified and
embedded in paraffin [3]. Sections of bone (5 μm) obtained
using a Leica RM 2165 microtome (Leica Microsystems,
Nussloch, Germany) were mounted on Superfrost Plus
slides (Fisher Scientific, Springfield, NJ) and used for
morphometric analysis, in situ hybridization, bone histo-
chemistry and bone immunohistochemistry. Femurs were
dehydrated in increasing concentrations of alcohol, embed-
ded in methylmethacrylate, sectioned into 5-μm sections
and mounted on slides for bone histomorphometry and
bone mineralized matrix assessment.
Serum biochemical determinations
Blood ionized Ca levels were determined using a Ca-sensitive
electrode (ICA Radiometer, Copenhagen, Denmark).
Serum P, creatinine and blood urea nitrogen (BUN)
levels were measured by standard laboratory methods.
Serum parathyroid (PTH) levels were measured using an
immunoradiometric assay for rat intact PTH (Immunotopics,
San Clemente, CA).
Morphometric assessment of growth plate cartilage
Morphometric assessment of the growth plate cartilage was
performed on sections stained with hematoxylin and eosin
and counter-stained with azure A [7]. The total width of the
growth plate cartilage at the proximal end of each tibia was
measured. An average of 30 width measurements from each
growth plate represented the final width determinations in
individual animals. The width of the zone occupied by
hypertrophic chondrocytes was measured by the same
method.
In situ hybridization
In situ hybridization was performed on sections of decal-
cified tibiae. [35S]-labeled riboprobes with a specific
activity of 1–2×109 cpm/μg in combination with the
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Gemini transcription kit (Promega, Madison, WI) was used
for MMP-9/gelatinase B. The Digoxigenin (DIG)-labeled
riboprobe (Roche Diagnostics, Mannheim, Germany) was
used for OPG. The number of cells expressing the specific
mRNA was counted and expressed as a percentage of the
number of positive cells to the total number of cells in the
appropriate growth plate zone where the mRNA expression
was localized.
Immunohistochemistry (BrdU labeling, TUNEL reaction,
TRAP)
Chondrocyte proliferation was assessed by the BrdU
staining kit (Zymed Laboratories). Immunoreactive cells
were counted, and data were expressed as the percentage of
cells that were positive within the proliferative zone and
hypertrophic zone immediately adjacent to the proliferative
zone. Chondrocyte apoptosis was detected using the
terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) reaction (ApopTag In Situ Apoptosis
Detection kits; Intergen, Purchase, NY). The rate of
apoptosis was calculated from the percentage of lower
hypertrophic chondrocytes that were positively stained.
The tartrate resistant acid phosphatase (TRAP) stain was
performed using α-naphthyl acid phosphate and sodium
tartrate salt followed by counterstaining with nuclear fast
green. TRAP-positive cells were counted in a rectangular
region defined by the area extending from the growth plate to
approximately 300 μm below the chondro-osseous junction in
the primary spongiosa. Results were expressed as the number
of TRAP-positive cells per area of the growth plate.
Assessment of the bone mineralized matrix and quantitative
bone histomorphometry
Sections of plastic-embedded non-decalcified femurs were
used for assessment of the bone mineralized matrix by Von
Kossa staining for mineralization. Quantitative bone histo-
morphometry was performed by the Goldner stain using a
Merz ocular grid [8] and the Osteoplan II Image Analysis
System (Kontron, Ecking, Germany). One hundred adjacent
fields of the examined region, which was defined by the
area in the primary spongiosa between 300 and 500 μm
below the growth plate, were counted under a microscope
at a magnification of 160×. Areas and perimeters were
measured by point counting and by linear intersection
methods. The results were reported using the standardized
methods proposed by Parfitt et al. [9]. BV was expressed as
a percentage of total tissue volume (TV), and osteoid
volume (OV) was expressed as a percentage of BV. The
perimeter measurements for the osteoid surface (OS) and
the eroded surface (ES) were expressed as a percentage of
the total bone surface (BS).
Statistical analysis
All results are expressed as mean values ± standard deviation
(SD). Data were evaluated by one-way analysis of variance
(ANOVA) with the Tukey HSD post-hoc test for comparisons
between groups using Statistical Package for the Social
Sciences ver. 13 software (SPSS, Chicago, IL). Probability
values of less than 5% were considered to be significant.
Results
Serum creatinine and BUN were significantly higher in
nephrectomized rats than in the intact rats which had normal
renal function. Although the serum creatinine levels in intact
rats were elevated, they remained significantly lower than
those in nephrectomized rats. The results from the creatinine
assay must have been a deviation since the BUN levels were
within the normal ranges, which indicated that the intact rats
had normal renal function. Serum creatinine levels in
nephrectomized rats were about 2 mg/dL, reflecting a model
of relatively severe uremia. Blood ionized Ca concentrations
were significantly higher and serum PTH values were
significantly lower in Nx-Ca rats than in Nx-Control rats.
Serum PTH values were significantly higher in the Nx-
Control rats than in the other groups. Serum P levels did not
differ among groups (Table 1).
Body weight and length did not differ among groups at
the beginning of the 4-week study period. The final weight
of rats fed a high Ca diet was significantly less than that of
their control counterparts and was lowest in Nx-Ca. Final
length was significantly less in Nx-Ca than in Intact-
Control rats but did not differ from the other groups.
Despite Nx-Ca rats having the shortest final length, the
length gain did not differ among the four groups. Final
tibial length was significantly less in the nephrectomized
animals than in their intact counterparts. The tibial length of
Nx-Ca rats was significantly shorter than that in the other
groups; however, there was no significant difference in
tibial length between Nx-Ca and Nx-Control rats (Table 2).
The width of the epiphyseal growth plate and the
hypertrophic zone in the proximal tibia did not differ among
the Intact-Control, Intact-Ca and Nx-Control rats. By contrast,
the epiphyseal growth plate was significantly wider in Nx-Ca
rats than in the other groups. This difference was the result of
an increase in the hypertrophic zone width immediately
adjacent to the primary spongiosa (Fig. 1).
To determine the underlying processes contributing to the
widening of the growth plate in Nx-Ca rats, chondrocyte
proliferation rate, chondrocyte apoptosis rate, matrix degra-
dation and osteoclastic activity were assessed. Chondrocyte
proliferation and apoptosis rate were not different among the
four groups (Table 3). By contrast, matrix degradation and
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osteoclastic activity were significantly lower in Nx-Ca rats
than in the other groups (Figs. 2, 3, respectively). The
mRNA expression for OPG was significantly increased in
Nx-Ca rats compared to the other groups (Fig. 4).
Quantitative bone histomorphometry analyses revealed
that Nx-Ca rats had higher BV than the other groups (Table 4,
Fig. 5). OVand OS were lower in Nx-Ca rats than in the Nx-
Control rats. Although OVand OS were higher in Nx-Ca rats
than in the intact rats, the difference did not reach statistical
significance (Table 4). ES was significantly higher in the Nx-
Control rats than in the other groups. There was no
difference in ES between the Nx-Ca and intact rats.
Discussion
In this study, the final weight was significantly less in rats
fed a high Ca diet than in their control counterparts and was
lowest in Nx-Ca rats. The poor weight gain in Nx-Ca rats
may have been confounded by the smaller amount of food
consumed by these rats as we did not ensure an equivalent
amount of caloric intake between the high Ca groups and
their control counterparts. The shorter final length of Nx-Ca
rats could partly be attributable to poor weight gain.
Therefore, a high Ca diet could potentially aggravate the
growth impairment in uremic rats. Nevertheless, tibial
length and length gain did not differ between Nx-Ca rats
and the Nx-Control rats.
The epiphyseal growth plates in Nx-Ca rats were
markedly enlarged due to an increased hypertrophic zone
width. The proliferative zone width in these animals
remained unchanged. The chondrocyte proliferation rate
was normal in our animal model compared with the
decreased chondrocyte proliferation in younger nephrec-
tomized rats given a high Ca diet reported by Sanchez et al.
(initial weight 90 g vs. 60 g) [10]. However, the decrease in
matrix degradation and osteoclastic activity were similar in
both studies [10].
OPG expression was significantly elevated in the nephrec-
tomized animals given a high Ca diet but not in intact rats on
Table 2 Anthropometric characteristics in Intact versus Nx rats on normal (control) and high Ca diets, respectively
Variables Intact-Control (n=11) Intact-Ca (n=11) Nx-Control (n=11) Nx-Ca (n=14)
Body weight (g)
Initial 91.6±4.0 91.5±2.9 89.5±4.3 91.3±2.8
Final 275.2±15.0 248.7±11.7a 235.7±13.6a 211.1±18.2b
Body length (cm)
Initial 27.3±0.7 27.5±0.8 26.0±0.7 26.3±1.0
Final 39.1±1.5 38.2±2.0 37.8±1.1 36.9±1.3a
Length gain (cm) 11.8±1.8 10.7±1.8 11.9±1.5 10.5±1.7
Final tibial length (cm) 3.90±0.07 3.80±0.09a 3.73±0.08a 3.70±0.06a,c
Values are given as the mean ± SD
a P<0.01 vs. Intact-Control
b P<0.01 vs. Intact-Control, Intact-Ca, Nx-Control
c P<0.05 vs. Intact-Ca
Table 1 Serum biochemical determination at sacrifice in intact versus nephrectomized (Nx) rats on normal (control) and high calcium (Ca) diets,
respectively
Variables Intact-Control (n=11) Intact-Ca (n=11) Nx-Control (n=11) Nx-Ca (n=14)
Blood urea nitrogen (mg/dL) 13.1±2.2 16.1±3.9 83.0±18.4a 72.4±14.7a
Serum creatinine (mg/dL) 1.5±0.1 1.4±0.2 2.1±0.3a 1.8±0.3a
Serum ionized calcium (mmol/L) 1.42±0.05 1.42±0.04 1.37±0.07 1.49±0.07b
Serum phosphorus (mg/dL) 8.8±1.0 8.2±1.3 7.4±1.4 6.8±2.2
Serum parathyroid hormone (pg/mL) 93.6±25.6 71.7±34.2 202.4±75.5a 34.6±28.3b
Intact-Control, Sham-nephrectomized control rats on standard diet; Intact-Ca, sham-nephrectomized rats on high Ca diet; Nx-Control,
nephrectomized control rats on standard diet; Nx-Ca, nephrectomized rats on high Ca diet
Values are given as the mean ± standard deviation (SD)
a P<0.01 vs. Intact-Control and Intact-Ca
b P<0.01 vs. Nx-Control
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the same diet. OPG inhibits osteoclastogenesis by competi-
tively binding to RANKL, thereby preventing RANKL from
binding and activating RANK [4]. OPG expression and
secretion are modulated by various metabolic regulators,
including PTH [11]. Studies in murine models revealed that
osteoclast differentiation is induced as the result of an
increased RANKL/OPG ratio in bone marrow stromal cells
following PTH exposure [12, 13]. Similar findings were
noted in humans receiving intermittent PTH treatment: serum
RANKL level increased while the serum OPG level
decreased [14]. Thus, the increased OPG expression in
uremic rats receiving a high Ca diet could be attributable to
significantly reduced PTH levels in this group of rats.
A suppressed PTH level similar that observed in our
animal model was also found in nephrectomized rats
receiving calcitriol therapy. Unlike our animal model, their
growth plate showed a normal width, decreased chondro-
cyte proliferation and normal BV [15]. This evidence raises
the possibility that high Ca may cause disturbances in the
growth plate and bone in uremic rats through other
additional mechanisms that are distinct from PTH suppres-
sion, such as by directly inhibiting MMP-9/gelatinase B
expression [10], or calcitriol could possibly counteract the
direct effect of PTH on OPG expression [16].
A decreased expression of MMP-9/gelatinase B could
interfere with angiogenesis, a crucial process in endochon-
dral ossification, as MMP-9/gelatinase B plays a major role
in hypertrophic zone vascularization and ossification. An
enlargement of the hypertrophic zone similar to the change
in the growth plate observed in our animal model was also
reported in homozygous mice with a null mutation in
MMP-9/gelatinase B. These animals showed delayed
angiogenesis and apoptosis of hypertrophic chondrocytes
[17]. Further investigations on angiogenic factors, including
the evaluation of vascular endothelial growth factor
(VEGF) expression in uremic rats fed a high Ca diet should
better elucidate the effects of Ca on alterations in growth
plate morphology.
Fig. 1 The width of total
growth plate and hypertrophic
zone in Intact versus nephrec-
tomized rats (Nx) on normal
(Control) and high calcium (Ca)
diets (magnification 40×). GP
Growth plate, Intact-Control,
sham-nephrectomized control
rats on standard diet, Intact-Ca
sham-nephrectomized rats on
high Ca diet, Nx-Control
nephrectomized control rats on
standard diet, Nx-Ca nephrec-
tomized rats on high Ca diet
Table 3 Percentage of chondrocyte proliferation rate and chondrocyte apoptosis rate in Intact versus Nx rats on normal (control) and high Ca
diets, respectively
Intact-Control (n=11) Intact-Ca (n=11) Nx-Control (n=11) Nx-Ca (n=14)
Chondrocyte proliferation rate (%) 69.5±6.0 69.8±3.5 72.8±3.6 67.5±6.3
Chondrocyte apoptosis rate (%) 4.82±2.54 4.75±1.61 4.86±1.30 2.75±1.12
Values are given as the mean ± SD
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Fig. 2 In situ hybridization of MMP-9/Gelatinase B mRNA express-
sion (arrowheads) in the chondro–osseous junction in Intact versus
nephrectomized rats (Nx) on normal (Control) and high calcium (Ca)
diets, respectively. The average number of MMP-9/Gelatinase B
expressing chondrocytes per total number of chondrocytes in the
chondro–osseous junction in each group is shown in the graph
(magnification 40×)
Fig. 3 Tartrate resistant acid
phosphatase (TRAP) staining
reveals osteoclasts (arrowheads)
in the chondro–osseous junction
in Intact versus nephrectomized
rats (Nx) on normal (Control)
and high calcium (Ca) diets,
respectively. Osteoclastic
activity was determined by
the average number of
osteoclasts per area of the
growth plate in the
chondro–osseous junction
(magnification 175×)
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The widening growth plates observed in our animal
model could be the result of increased OPG expression by
hypertrophic chondrocytes, resulting in an inhibition of
osteoclastic breakdown of the growth plate calcified
cartilage. Although increased growth plate width has been
observed in fetal rats exposed to bisphosphonates, the
underlying mechanism of alterations in growth plate
morphology from this antiresorptive agent is likely to be
the result of the inhibition of collagen fiber breakdown, as
shown in the study by Kim et al. [18]. Moreover,
Fig. 5 The bar graph demon-
strates trabecular bone area
measurement expressed as a
percentage of total tissue area in
the Intact versus nephrectomized
rats (Nx) on normal (Control)
and high calcium (Ca) diets. The
lower panel shows the bone
mineralized matrix assessed by
Von Kossa staining of sections
of non-decalcified femur
(magnification 6.3×)
Fig. 4 In situ hybridization of OPG mRNA expresssion in the
chondro–osseous junction in Intact versus nephrectomized rats (Nx)
on normal (Control) and high calcium (Ca) diets, respectively. The
average number of OPG expressing chondrocytes per total number of
chondrocytes in the chondro–osseous junction in each group was
shown in the graph (magnification 175×)
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bisphosphonates prevent bone resorption via different
mechanisms independent of the OPG pathway, as supported
by the fact that bisphosphonates effectively inhibit bone
resorption and prevent bone loss even in the OPG knockout
mice [19].
Concurrent with decreased osteoclastic activity and
increased OPG expression, we found an increase in the
bone mineralized matrix and BV in nephrectomized animals
given a high Ca diet that resemble the findings presented in
transgenic mice overexpressing the OPG gene [5]. More
evidence supporting the bone protective effect of OPG has
been noted in ovariectomized and orchiectomized animals
receiving recombinant OPG administration as their BV and
bone density were improved. These animals demonstrated
decreased osteoclastogenesis and decreased bone loss [6,
20].
Osteoclastic activity assessed by TRAP staining was
markedly decreased in Nx-Ca rats when compared with that
in the other groups. By contrast, the bone resorption or ES,
assessed by bone histomorphometry, did not significantly
differ from that in the intact groups. However, the ES of
Nx-Ca rats was significantly decreased when compared
with that of the Nx-Control rts. Although the OV and OS
were higher in Nx-Ca rats than in the intact groups, the
difference did not reach statistical significance, but OV and
OS were less in Nx-Ca rats than in the Nx-Control animals,
suggesting that osteoblastic activity was decreased in the
former when compared with the latter. Increased OPG
expression may potentially modify osteoblastic function in
uremic animals. However, the definite role of OPG on
osteoblastic activity has to be further investigated. In-
creased BV in our Nx-Ca animals most likely resulted from
decreased osteoclastic activity as the osteoblastic function
was not significantly increased.
Contrary to studies in animal models, in hemodialysis
patients, high serum OPG levels were found in those who
had low bone mineral density. Serum OPG in this setting
does not appear to protect the skeleton against the increased
bone resorption of renal osteodystrophy [21]. It has been
postulated that OPG in the serum is bound to plasma
proteins and thus inactive [22]. Moreover, serum OPG
levels may not entirely reflect OPG expression in the bone
as elevation of serum OPG levels may be the result of
reduced renal clearance and the lack of its elimination
through the dialysis membrane [23].
In summary, uremic animals receiving a diet highly
supplemented with Ca demonstrated decreased osteoclastic
activity and increased BV associated with increased OPG
expression. As RANK, RANKL and OPG play an integral
role in the regulatory pathway of osteoclastogenesis,
elucidating the regulation of the RANK/RANKL/OPG
system in uremic animals receiving a high Ca diet could
be initially performed by measuring only OPG expression.
Even though we have shown that the OPG level was
increased in such animals, the roles of RANK and RANKL
on the bone remodeling process in uremic animals
receiving a high Ca diet should be further examined.
Disturbances of osteoclastogenesis have been shown to
interfere with the bone remodeling process and result in an
increased risk of recurrent fractures [24]. Conversely,
increased BV should increase bone strength and prevent
fractures, as has been shown in several reports [25, 26].
Although the bone quantity was increased in these animals,
the bone quality is yet to be determined. To which extent
nutrition interferes with the metabolism on the growth
plates in uremic rats receiving a high Ca diet should be
further assessed as the data on food intake and food
conversion ratio were not available and the weight gain was
significantly less in these animals.
As previously shown in Table 1, serum PTH levels in the
Ca-supplemented nephrectomized rats in our experiment
were severely suppressed to less than 50% of the mean
value observed in the intact rats. Such an overcorrection of
SHPT should be avoided in the clinical setting to allow
normal bone remodeling to occur. This animal model
reflects a rare but relevant clinical condition which needs
Table 4 Bone histomorphometric measurement in Intact versus nephrectomized Nx rats on normal (control) and high Ca diets
Bone histomorphometric parameters Intact-Control Intact-Ca Nx-Control Nx-Ca
BV/TV% 12.36±2.24 15.26±4.59 9.97±2.24 24.68±2.04c
OV/BV% 0.21±0.39 0.16±0.11 1.99±0.31a 0.39±0.07d
OS/BS% 0.62±0.80 0.31±0.61 7.79±2.93a 1.87±0.70d
ES/BS% 0.64±0.74 1.00±0.38 4.79±1.59b 0.32±0.17
BV, Trabecular bone volume; TV, total tissue volume; OV, osteoid volume; OS, osteoid surface; BS, total bone surface; ES, eroded surface
Values are given as the mean ± SD
a P<0.01 vs. Intact-Control and Intact-Ca
b P<0.01 vs. Intact-Control, Intact-Ca and Nx-Ca
c P<0.01 vs. Intact-Control, Intact-Ca and Nx-Control
d P<0.01 vs. Nx-Control
2318 Pediatr Nephrol (2010) 25:2311–2319
to be prevented by all available means, including the use of
calcium-free phosphate binders and low calcium dialysate
concentrations.
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